Amylyx Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net income was USD 20.89 million compared to net loss of USD 53.76 million a year ago. Basic earnings per share from continuing operations was USD 0.31 compared to basic loss per share from continuing operations of USD 0.92 a year ago. Diluted earnings per share from continuing operations was USD 0.3 compared to diluted loss per share from continuing operations of USD 0.92 a year ago.
For the nine months, net income was USD 44.54 million compared to net loss of USD 155.67 million a year ago. Basic earnings per share from continuing operations was USD 0.66 compared to basic loss per share from continuing operations of USD 2.77 a year ago. Diluted earnings per share from continuing operations was USD 0.63 compared to diluted loss per share from continuing operations of USD 2.77 a year ago.